Crinetics Pharmaceuticals Inc
CRNX41.450USD
+1.450+3.63%
收盤 11/10, 16:00（美東）報價延遲15分鐘
3.92B總市值
虧損本益比TTM
關於 Crinetics Pharmaceuticals Inc 公司
Crinetics Pharmaceuticals, Inc. 是一家臨牀階段製藥公司，專注於發現、開發和商業化罕見內分泌疾病和內分泌相關腫瘤的治療方法。其 Paltusotine 是一種口服生長抑素受體 2 型 (SST2) 激動劑，目前正處於治療肢端肥大症的 3 期臨牀開發階段和治療與神經內分泌腫瘤相關的類癌綜合徵的 2 期臨牀開發階段。該公司已在 CRN04894 的 1 期臨牀研究中展示了藥理學概念驗證，CRN04894 是一種口服 ACTH 拮抗劑，目前正處於治療先天性腎上腺增生和庫欣病的 2 期臨牀研究階段。其候選藥物是口服的小分子新化學實體，是公司內部藥物發現工作的結果，包括針對各種內分泌疾病（如甲狀旁腺功能亢進症、多囊腎病、格雷夫斯病、甲狀腺眼病、糖尿病和肥胖症）的其他項目。
Crinetics Pharmaceuticals Inc簡介
公司代碼CRNX
公司名稱Crinetics Pharmaceuticals Inc
上市日期Jul 18, 2018
CEODr. R. Scott Struthers, Ph.D.
員工數量437
證券類型Ordinary Share
年結日Jul 18
公司地址6055 Lusk Blvd.
城市SAN DIEGO
上市交易所NASDAQ Global Select Consolidated
國家United States of America
郵編92121
電話18584506464
網址https://www.crinetics.com/
公司代碼CRNX
上市日期Jul 18, 2018
CEODr. R. Scott Struthers, Ph.D.
Crinetics Pharmaceuticals Inc公司高管
名稱
名稱/職務
職務
持股
持股變動
Dr. Wendell Wierenga, Ph.D.
Dr. Wendell Wierenga, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
116.15K
+6.32%
Dr. Stephen F. Betz, Ph.D.
Dr. Stephen F. Betz, Ph.D.
Co-Founder, Chief Scientific Officer
Co-Founder, Chief Scientific Officer
99.28K
-8.58%
Mr. Tobin C. (Toby) Schilke
Mr. Tobin C. (Toby) Schilke
Chief Financial Officer
Chief Financial Officer
52.00K
--
Ms. Caren Deardorf
Ms. Caren Deardorf
Independent Director
Independent Director
16.30K
+73.40%
Dr. Camille L. Bedrosian, M.D.
Dr. Camille L. Bedrosian, M.D.
Independent Director
Independent Director
16.30K
+73.40%
Dr. Weston A. Nichols, Ph.D.
Dr. Weston A. Nichols, Ph.D.
Independent Director
Independent Director
16.30K
+73.40%
Ms. Stephanie S. Okey
Ms. Stephanie S. Okey
Independent Director
Independent Director
16.30K
+73.40%
Dr. Dana Pizzuti, M.D.
Dr. Dana Pizzuti, M.D.
Chief Medical and Development Officer
Chief Medical and Development Officer
--
--
Ms. Isabel Kalofonos
Ms. Isabel Kalofonos
Chief Commercial Officer
Chief Commercial Officer
--
--
Mr. Matthew K. (Matt) Fust
Mr. Matthew K. (Matt) Fust
Independent Director
Independent Director
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Dr. Wendell Wierenga, Ph.D.
Dr. Wendell Wierenga, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
116.15K
+6.32%
Dr. Stephen F. Betz, Ph.D.
Dr. Stephen F. Betz, Ph.D.
Co-Founder, Chief Scientific Officer
Co-Founder, Chief Scientific Officer
99.28K
-8.58%
Mr. Tobin C. (Toby) Schilke
Mr. Tobin C. (Toby) Schilke
Chief Financial Officer
Chief Financial Officer
52.00K
--
Ms. Caren Deardorf
Ms. Caren Deardorf
Independent Director
Independent Director
16.30K
+73.40%
Dr. Camille L. Bedrosian, M.D.
Dr. Camille L. Bedrosian, M.D.
Independent Director
Independent Director
16.30K
+73.40%
Dr. Weston A. Nichols, Ph.D.
Dr. Weston A. Nichols, Ph.D.
Independent Director
Independent Director
16.30K
+73.40%
收入明細
暫無數據
暫無數據
業務
地區
暫無數據
股東統計
更新時間: 8月16日 週六
更新時間: 8月16日 週六
持股股東
股東類型
持股股東
持股股東
佔比
Fidelity Management & Research Company LLC
13.09%
The Vanguard Group, Inc.
9.64%
BlackRock Institutional Trust Company, N.A.
6.85%
Driehaus Capital Management, LLC
6.74%
Wellington Management Company, LLP
6.12%
其他
57.55%
持股股東
持股股東
佔比
Fidelity Management & Research Company LLC
13.09%
The Vanguard Group, Inc.
9.64%
BlackRock Institutional Trust Company, N.A.
6.85%
Driehaus Capital Management, LLC
6.74%
Wellington Management Company, LLP
6.12%
其他
57.55%
股東類型
持股股東
佔比
Investment Advisor
51.93%
Investment Advisor/Hedge Fund
42.57%
Hedge Fund
14.49%
Research Firm
2.39%
Individual Investor
1.99%
Venture Capital
1.98%
Private Equity
1.22%
Pension Fund
0.49%
Bank and Trust
0.37%
機構持股
更新時間: 10月1日 週三
更新時間: 10月1日 週三
報告期間
機構數
持股數
持股佔比
持股變動
2025Q3
523
108.96M
114.82%
-4.85M
2025Q2
515
106.62M
113.80%
-6.60M
2025Q1
523
107.13M
114.60%
-8.74M
2024Q4
502
104.03M
112.03%
+3.16M
2024Q3
472
88.80M
110.94%
-9.89M
2024Q2
454
86.41M
109.20%
-10.36M
2024Q1
412
84.26M
107.74%
-4.10M
2023Q4
379
74.72M
112.09%
-6.67M
2023Q3
357
73.94M
113.29%
+8.54M
2023Q2
317
58.83M
107.87%
-6.38M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Fidelity Management & Research Company LLC
12.42M
13.19%
+97.46K
+0.79%
Jun 30, 2025
The Vanguard Group, Inc.
9.24M
9.81%
-55.47K
-0.60%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
6.50M
6.9%
-274.52K
-4.05%
Jun 30, 2025
Driehaus Capital Management, LLC
6.40M
6.8%
+160.12K
+2.57%
Jun 30, 2025
Wellington Management Company, LLP
5.81M
6.17%
-1.08M
-15.73%
Jun 30, 2025
Farallon Capital Management, L.L.C.
5.63M
5.97%
+979.00K
+21.07%
Aug 29, 2025
T. Rowe Price Associates, Inc.
5.49M
5.83%
+472.19K
+9.40%
Jun 30, 2025
EcoR1 Capital, LLC
4.29M
4.55%
--
--
Jun 30, 2025
Janus Henderson Investors
3.41M
3.62%
-14.12K
-0.41%
Jun 30, 2025
State Street Investment Management (US)
3.22M
3.42%
-58.97K
-1.80%
Jun 30, 2025
查看更多
持股ETF
更新時間: 11月6日 週四
更新時間: 11月6日 週四
機構名稱
佔比
SPDR S&P Pharmaceuticals ETF
2.86%
ALPS Medical Breakthroughs ETF
2.44%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
2.14%
Tema Heart & Health ETF
1.87%
iShares U.S. Pharmaceuticals ETF
1.45%
First Trust Multi-Manager Small Cap Opportunities ETF
0.97%
Virtus LifeSci Biotech Clinical Trials ETF
0.93%
ProShares Ultra Nasdaq Biotechnology
0.41%
Invesco Nasdaq Biotechnology ETF
0.39%
iShares Biotechnology ETF
0.34%
查看更多
SPDR S&P Pharmaceuticals ETF
佔比2.86%
ALPS Medical Breakthroughs ETF
佔比2.44%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
佔比2.14%
Tema Heart & Health ETF
佔比1.87%
iShares U.S. Pharmaceuticals ETF
佔比1.45%
First Trust Multi-Manager Small Cap Opportunities ETF
佔比0.97%
Virtus LifeSci Biotech Clinical Trials ETF
佔比0.93%
ProShares Ultra Nasdaq Biotechnology
佔比0.41%
Invesco Nasdaq Biotechnology ETF
佔比0.39%
iShares Biotechnology ETF
佔比0.34%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
